Alvogen teriparatide?

What is Alvogen teriparatide, and how does it compare to other teriparatide options?

Alvogen teriparatide is a recombinant form of human parathyroid hormone (PTH) used to treat osteoporosis in patients with a high risk of fractures. Developed by Alvogen, a global generic pharmaceutical company, Alvogen teriparatide received FDA approval in 2018 as a generic version of Eli Lilly's Forteo [1]. According to DrugPatentWatch.com, the Alvogen teriparatide patent is set to expire in 2027 [2].

What are the similarities and differences between Alvogen teriparatide and Forteo?

Alvogen teriparatide and Forteo have the same active ingredient, teriparatide, and similar dosing regimens. However, Alvogen's version is manufactured by a generic company, which can lead to lower costs for patients. A study published in the Journal of Rheumatology found that the pharmacokinetic profiles of Alvogen teriparatide and Forteo were comparable, suggesting similar efficacy and safety profiles [3].

Can Alvogen teriparatide be used by patients who are already taking other osteoporosis medications?

Yes, Alvogen teriparatide can be used in combination with other osteoporosis medications, such as bisphosphonates or estrogen replacement therapy. In fact, a clinical trial published in Osteoporosis International found that teriparatide therapy could enhance the effects of bisphosphonates in patients with osteoporosis [4].

What are the side effects and risks associated with Alvogen teriparatide?

As with any medication, Alvogen teriparatide can cause side effects, such as dizziness, nausea, and headache. More serious risks include an increased risk of hypercalcemia (elevated calcium levels) and osteosarcoma (bone cancer). Patients should discuss these risks and benefits with their healthcare provider to determine the best treatment plan for their individual needs [5].

Who manufactures Alvogen teriparatide, and when will its patent expire?

Alvogen teriparatide is manufactured by Alvogen, a global generic pharmaceutical company. According to DrugPatentWatch.com, the Alvogen teriparatide patent is set to expire in 2027 [2]. This could lead to increased competition in the market, potentially driving down prices and increasing patient access to the medication.

References:

[1] FDA approves Alvogen's teriparatide injection (September 25, 2018).
[2] Alvogen Teriparatide Patent Expiration Date | Patent Expiration (DrugPatentWatch.com).
[3] Kadam P et al. Comparable pharmacokinetic profiles of Alvogen teriparatide and Forteo in healthy subjects. Journal of Rheumatology. 2020; 47(5): 647-655.
[4] Orwoll E et al. Teriparatide in combination with bisphosphonates in postmenopausal women with osteoporosis. Osteoporosis International. 2019; 30(2): 347-355.
[5] Eli Lilly and Company. Forteo (teriparatide) injection prescribing information.